Lumvoa approved and launched in TED; elegrobart BLA submission determines whether Viridian builds a two-drug franchise or peaks with one

Viridian Therapeutics is a commercial-stage company that develops targeted cancer drugs for thyroid eye disease, with an approved lead product called Lumvoa and a second candidate not yet approved awaiting regulatory decision.

Viridian launched Lumvoa, an FDA-approved IGF-1R inhibitor for thyroid eye disease, just weeks after completing its IPO, giving it a commercial asset and $982M in cash projected to sustain through profitability. Elegrobart, a subcutaneous anti-IGF-1R antibody, met primary endpoints in both active and chronic TED Phase 3 trials; approvability on that single-arm-style BLA filing determines whether Viridian captures a second, more convenient formulation franchise. The core risk is competition from Amgen's Tepezza, which already has entrenched prescriber relationships and a head start that a subcutaneous convenience argument alone may not overcome.